These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1229659)

  • 1. [Release of dopamine and symptoms of schizophrenia].
    Devis D
    Vestn Akad Med Nauk SSSR; 1975; (9):55-60. PubMed ID: 1229659
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine, psychomotor stimulants, and schizophrenia: effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics.
    Janowsky DS; Davis JM
    Adv Biochem Psychopharmacol; 1974; 12(0):317-23. PubMed ID: 4608582
    [No Abstract]   [Full Text] [Related]  

  • 3. Biochemistry and the schizophrenia. Old concepts and new hypothesis.
    Berger PA
    J Nerv Ment Dis; 1981 Feb; 169(2):90-9. PubMed ID: 7009786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychopharmacology of monoamines and their regulatory enzymes.
    Lipton MA
    Adv Biochem Psychopharmacol; 1974; 12(0):443-54. PubMed ID: 4153941
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of thioproperazine on dopamine and noradrenaline metabolism in chronic schizophrenia].
    Panisset VC; Albert JM; Rocheleau LP; Dhaiti G; Tétreault L
    Laval Med; 1970 Sep; 41(7):917-22. PubMed ID: 4396422
    [No Abstract]   [Full Text] [Related]  

  • 6. [Basics of the drug therapy for attention deficit hyperactivity disorders in adolescents].
    Airaksinen E; Airaksinen MM
    Duodecim; 2003; 119(16):1553-62. PubMed ID: 14535028
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain.
    Easton N; Steward C; Marshall F; Fone K; Marsden C
    Neuropharmacology; 2007 Feb; 52(2):405-14. PubMed ID: 17020775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Stimulants in the treatment of hyperkinetic behavior disorders].
    Barkai A
    Harefuah; 1971 Mar; 80(6):298-302. PubMed ID: 4946564
    [No Abstract]   [Full Text] [Related]  

  • 9. A two factor theory of schizophrenia.
    Davis JM
    J Psychiatr Res; 1974; 11():25-9. PubMed ID: 4477776
    [No Abstract]   [Full Text] [Related]  

  • 10. Toward hypotheses for a biochemical component in the vulnerability to schizophrenia.
    Kety SS
    Semin Psychiatry; 1972 Aug; 4(3):233-8. PubMed ID: 4155537
    [No Abstract]   [Full Text] [Related]  

  • 11. Amphetamines, valuable adjunct in treatment of Parkinsonism.
    Miller E; Nieburg HA
    N Y State J Med; 1973 Nov; 73(22):2657-61. PubMed ID: 4519081
    [No Abstract]   [Full Text] [Related]  

  • 12. Neurobiology of dopamine in schizophrenia.
    Guillin O; Abi-Dargham A; Laruelle M
    Int Rev Neurobiol; 2007; 78():1-39. PubMed ID: 17349856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine and norepinephrine uptake by rat brain synaptosomes: relative inhibitory potencies of 1- and d-amphetamine and amantadine.
    Thornburg JE; Moore KE
    Res Commun Chem Pathol Pharmacol; 1973 Jan; 5(1):81-9. PubMed ID: 4686111
    [No Abstract]   [Full Text] [Related]  

  • 14. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor.
    Snyder SH
    Am J Psychiatry; 1976 Feb; 133(2):197-202. PubMed ID: 1251927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biochemical studies of schizophrenia].
    Kakimoto Y
    Nihon Rinsho; 1976 Sep; 34(9):2706-11. PubMed ID: 1033308
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic possibilities of cysteamine in the treatment of schizophrenia.
    Pae CU; Lee C; Paik IH
    Med Hypotheses; 2007; 69(1):199-202. PubMed ID: 17166669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the value of measuring dopamine, norepinephrine and their metabolites in schizophrenia.
    Kahn RS; Davidson M
    Neuropsychopharmacology; 1993 Feb; 8(2):93-5. PubMed ID: 8471131
    [No Abstract]   [Full Text] [Related]  

  • 18. [Urinary excretion of adrenalin, noradrenalin and dopamine during the 2 hours following the administration of amphetamine].
    Beauvallet M; Fugazza J; Legrand M
    C R Seances Soc Biol Fil; 1966; 160(3):546-50. PubMed ID: 4224408
    [No Abstract]   [Full Text] [Related]  

  • 19. d-Amphetamine versus methylphenidate effects in depressed inpatients.
    Little KY
    J Clin Psychiatry; 1993 Sep; 54(9):349-55. PubMed ID: 8407854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role if dopamine and norepinephrine uptake inhibition in mediating the central effects of d-amphetamine in vivo.
    Feigenbaum JJ; Yanai J; Blass RB
    Res Commun Chem Pathol Pharmacol; 1982 Feb; 35(2):333-5. PubMed ID: 7071417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.